AVROBIO Inc (NASDAQ:AVRO)

7.59
Delayed Data
As of Jul 23
 -0.17 / -2.19%
Today’s Change
7.27
Today|||52-Week Range
20.07
-45.55%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$314.5M

Company Description

Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm's clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Cambridge, MA.

Contact Information

Avrobio, Inc.
One Kendall Square
Cambridge Massachusetts 02139
P:(617) 914-8420
Investor Relations:

Employees

Shareholders

Other institutional42.10%
Mutual fund holders36.93%
Individual stakeholders32.25%

Top Executives

Geoff MacKayPresident, Chief Executive Officer & Director
Matt ArnoldHead-Operations
Erik OstrowskiChief Financial Officer & Treasurer
Christopher MasonChief Scientific Officer
Kim RaineriChief Manufacturing & Technology Officer